Clinical Trial Update: Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids [Phase 4]

View source ↗

Summary

This Phase 4 study evaluates whether omalizumab (Xolair) can improve the tolerability of specific immunotherapy in patients with moderate-to-severe allergic ast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: University of Mississippi Medical Center | Conditions: Asthma | Phase 4 | Status: COMPLETED